Last reviewed 2026-04-20 · How we verify

Fluoromar (FLUROXENE)

Phase 2 active Small molecule

Fluoromar (generic name: FLUROXENE) is a fluroxene drug. It is currently in Phase 2 development for General anesthesia.

Fluoromar works by inducing unconsciousness and amnesia through its effects on the central nervous system.

Fluoromar, also known as Fluroxene, is a small molecule drug in the fluroxene class. It is used for general anesthesia, but its target and exact mechanism of action are unknown. The commercial status of Fluoromar is unclear, and it may be patented or off-patent. As a general anesthetic, Fluoromar is used to induce unconsciousness and amnesia in patients undergoing surgery. However, more information is needed to fully understand its safety profile and usage.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLUROXENE
Drug class	fluroxene
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain as a busy city with many different neighborhoods. Fluoromar helps quiet down the neighborhoods that control consciousness and memory, making it easier for patients to relax and undergo surgery without feeling pain or remembering the experience.

Approved indications

General anesthesia

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluoromar CI brief — competitive landscape report
Fluoromar updates RSS · CI watch RSS

Frequently asked questions about Fluoromar

What is Fluoromar?

Fluoromar (FLUROXENE) is a fluroxene drug, indicated for General anesthesia.

How does Fluoromar work?

Fluoromar works by inducing unconsciousness and amnesia through its effects on the central nervous system.

What is Fluoromar used for?

Fluoromar is indicated for General anesthesia.

What is the generic name of Fluoromar?

FLUROXENE is the generic (nonproprietary) name of Fluoromar.

What drug class is Fluoromar in?

Fluoromar belongs to the fluroxene class. See all fluroxene drugs at /class/fluroxene.

What development phase is Fluoromar in?

Fluoromar is in Phase 2.

Drug class: All fluroxene drugs
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for General anesthesia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing